HOLON, Israel, March 1, 2019 /PRNewswire/ -- Compugen Ltd.
(NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and
leader in predictive target discovery, today announced that its
Phase 1 clinical trial evaluating COM701, a first-in-class
therapeutic antibody targeting PVRIG, was featured in a
trial-in-progress at The ASCO-SITC Clinical Immuno-Oncology
Symposium. In poster titled "A Phase 1 Study Evaluating
COM701 in Patients With Advanced Solid Tumors," the Company
reported that the third single subject dose cohort has been
completed with no dose-limiting toxicities (DLTs) reported.
Clinical and laboratory assessment for safety and tolerability is
ongoing for the fourth dosing cohort. The poster presented at the
symposium is available on Compugen's website.
"We continue to see significant interest in the study from
investigators as they recognize the potential and differentiation
of COM701 relative to other checkpoint inhibitors in development,"
said Henry Adewoye, M.D., Chief
Medical Officer at Compugen. "After recently adding Massachusetts
General Hospital and the University of
Chicago, two additional leading medical centers with
significant experience in immuno-oncology, we now have five sites
recruiting patients for this Phase 1 study. Patient enrollment is
also on track and we expect to complete enrollment of both the
monotherapy and dual combination dose escalation arms of the study
this year."
The sites currently recruiting patients are: The START center in
San Antonio, Texas; The
University of Tennessee West Cancer
Center in Memphis, Tennessee;
Sarah Cannon Research Institute in Nashville, Tennessee; Massachusetts General
Hospital in Boston, Massachusetts;
and the University of Chicago in
Chicago, Illinois. The study is
expected to include up to ten sites and enroll approximately 140
patients.
Updated information on the COM701 Phase 1 clinical study will be
next featured in a trial-in-progress poster at The AACR Annual
Meeting 2019 taking place March
29-April 3, 2019 at the Georgia World Congress Center,
Atlanta, GA.
About the COM701 Phase 1 Study
This Phase 1 open-label clinical trial is designed to assess the
safety and tolerability of administering escalating doses of COM701
monotherapy as well as combination administration with a PD-1
inhibitor in patients with advanced solid tumors. Additionally, the
trial will evaluate evidence of preliminary antitumor activity of
COM701 as a monotherapy as well as in combination with a PD-1
inhibitor in patients with selected tumor types, including
non-small cell lung cancer, ovarian cancer, breast cancer and
endometrial cancer. Additional information is available here.
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel with facilities in
South San Francisco, CA.
Compugen's ordinary shares are listed on Nasdaq and the Tel Aviv
Stock Exchange under the ticker symbol CGEN. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," "confident," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors, including the
ability to finance the Company, are more fully discussed in the
"Risk Factors" section of Compugen's most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-presents-update-on-com701-phase-1-trial-at-asco-sitc-clinical-immuno-oncology-symposium-300804906.html
SOURCE Compugen Ltd.